Scholars@Duke
Sin Tiong Ong

Sin Tiong Ong

Professor of Medicine
Medicine, Medical Oncology
sintiong.ong@duke-nus.edu.sg
406 Seeley Mudd Bldg, Box 3406, Durham, NC 27710

Scholarly Works - Conferences

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Conference Blood · November 3, 2025 AbstractBackground Evidence has accumulated that somatic mutations in myeloid genes other than BCR::ABL1 at CML diagnosis are associated wi ... Full text Cite

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Conference Blood · November 3, 2025 AbstractIntroduction Treatment-free remission (TFR) remains unpredictable in chronic myeloid leukemia (CML) management, with half of patien ... Full text Cite

Single-cell chromatin profiling reveals early epigenetic reprogramming, subtype-specific regulatory networks, and JAK/STAT–IRF vulnerabilities in high-risk chronic myeloid leukemia

Conference Blood · November 3, 2025 AbstractMyeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML), are oncogene-driven blood cancers arising from hemat ... Full text Cite

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Conference Blood · November 5, 2024 Introduction: Therapy resistance driven by Leukemic Stem/Progenitor Cells (LSPCs) remains a challenge in Chronic Myeloid Leukemia (CML).Recent studies indicate that Tyrosine Kinase Inhibi ... Full text Cite

Leukaemia Exposure Alters the Transcriptional Profile and Function of Macrophages in the Bone Marrow Niche

Conference Blood · November 2, 2023 These authors contributed equally to this work: Martha M. Zarou & Amy DawsonMacrophages are fundamental cells of the innate immune system. Bone marrow (BM) resident macrophages are i ... Full text Cite

Mnk1/2 and Abl inhibitions for the treatment of blast crisis chronic myelogenous leukemia

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2017 Link to item Cite

The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia

Conference Blood · December 3, 2015 AbstractThe transition from chronic phase (CP) to blast crisis (BC) chronic myeloid leukemia (CML) is characterized by reprogramming of the CML transcriptome (Radich et al. PNAS 2006), and shortened survival ... Full text Cite

Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

Conference Blood · May 22, 2014 C-abl oncogene 1, nonreceptor tyrosine kinase (ABL1) kinase inhibitors such as imatinib mesylate (imatinib) are effective in managing chronic myeloid leukemia (CML) but incapable of eliminating leukemia stem cells (LSCs), suggesting that kinase-independent ... Full text Link to item Cite